
|Articles|April 30, 2003
Nomogram for BPH progression risk offers aid in clinical decision-making
Chicago-Data from nearly 5,000 participants in the phase III studiesof dutasteride (Avodart) have been used to develop a nomogram for predictingthe probability that an individual patient with BPH will develop acute urinaryretention or require surgical intervention within 2 years and how that riskmay be altered by initiating dutasteride therapy.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer
3
Individualizing androgen pathway therapy in mCSPC
4
BOND-003 Cohort C: Efficacy Results
5








